Vaccine

Keyphrases

Publications

volume 41, number 8, 2023

Ranju Baral, Ann Levin, Chris Odero, Clint Pecenka, John Tanko Bawa, Kwadwo Odei Antwi-Agyei, Kwame Amponsa-Achaino, Mike Nenani Chisema, Rose Eddah Jalango, Rouden Mkisi, Scott Gordon, Winthrop Morgan, Farzana Muhib
Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program. Vaccine 41 (8) (2023)
Josefina B Parodi, Agustín Indavere, Pamela Bobadilla Jacob, Guillermo C Toledo, Rubén G Micali, Gabriel Waisman, Walter Masson, Eduardo D Epstein, Melina S Huerin
Impact of COVID-19 vaccination in post-COVID cardiac complications. Vaccine 41 (8) (2023)
Ashraf Moini, Maryam Rabiei, Reihaneh Pirjani, Amene Abiri, Arezoo Maleki-Hajiagha
COVID‑19 vaccine hesitancy among pregnant women and their reported reasons for vaccine refusal - A prospective study in Tehran, Iran. Vaccine 41 (8) (2023)
Matthew Z Dudley, Holly B Schuh, Jana Shaw, Rajiv N Rimal, Steven A Harvey, Kristian R Balgobin, Alexander J Zapf, Daniel A Salmon
COVID-19 vaccination among different types of US Healthcare Personnel. Vaccine 41 (8) (2023)
Ching-Ying Huang, Hsin Chi, Lung Chang, Nan-Chang Chiu
Typical time courses and appearance of skin reactions at the site of Bacillus Calmette-Guérin vaccination for infants inoculated at 5-8 months of age. Vaccine 41 (8) (2023)

volume 41, number 9, 2023

Yanmin Zhang, Daoyuan Na, Weijian Zhang, Xuping Liu, Shiwei Miao, Wen-Song Tan, Liang Zhao
Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform. Vaccine 41 (9) (2023)
María Gabriela Matta, Laura Pulido, Juan José Herrera-Paz, José M Picco, Sebastian Wolff, Gary Tse, Sebastian Garcia-Zamora
Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina. Vaccine 41 (9) (2023)
Ariella Grossman-Giron, Dana Tzur Bitan, Sharon Shemesh, Yael Mayer, Noga Shiffman, Yuval Bloch
COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel. Vaccine 41 (9) (2023)
Ami Harbin, Naomi Laventhal, Mark Navin
Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19. Vaccine 41 (9) (2023)
James S Ford, Sam G Rouleau, Jenny L Wagner, Christopher B Adams, Larissa S May, Aman K Parikh, James F Holmes
Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department. Vaccine 41 (9) (2023)
María Gabriela Matta, Laura Pulido, Juan José Herrera-Paz, José M Picco, Sebastian Wolff, Gary Tse, Sebastian Garcia-Zamora
Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina. Vaccine 41 (9) (2023)
Yoshifumi Uwamino, Takashi Yokoyama, Yasunori Sato, Ayako Shibata, Toshinobu Kurafuji, Akiko Tanabe, Masayo Noguchi, Tomoko Arai, Akemi Ohno, Hiromitsu Yokota, Ho Namkoong, Tomoyasu Nishimura, Kenjiro Kosaki, Naoki Hasegawa, Masatoshi Wakui, Mitsuru Murata, Hiromichi Matsushita
Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine. Vaccine 41 (9) (2023)
James S Ford, Sam G Rouleau, Jenny L Wagner, Christopher B Adams, Larissa S May, Aman K Parikh, James F Holmes
Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department. Vaccine 41 (9) (2023)
Ami Harbin, Naomi Laventhal, Mark Navin
Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19. Vaccine 41 (9) (2023)
Yoshifumi Uwamino, Takashi Yokoyama, Yasunori Sato, Ayako Shibata, Toshinobu Kurafuji, Akiko Tanabe, Masayo Noguchi, Tomoko Arai, Akemi Ohno, Hiromitsu Yokota, Ho Namkoong, Tomoyasu Nishimura, Kenjiro Kosaki, Naoki Hasegawa, Masatoshi Wakui, Mitsuru Murata, Hiromichi Matsushita
Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine. Vaccine 41 (9) (2023)
Simon B Gressens, Aurélie Wiedemann, Marie Déchenaud, Jehan Dupuis, Sébastien Gallien, Giovanna Melica, Corinne Haioun, François Lemonnier, Yves Levy
Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies. Vaccine 41 (9) (2023)
Srihari Seshadri, Stacey W Martin, Susan L Hills, Limone C Collins
Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019. Vaccine 41 (9) (2023)
Abraham M Getaneh, Xiao Li, Zhuxin Mao, Caroline K Johannesen, Elisa Barbieri, Jojanneke van Summeren, Xin Wang, Sabine Tong, Eugenio Baraldi, Emily Phijffer, Caterina Rizzo, Maarten van Wijhe, Terho Heikkinen, Louis Bont, Lander Willem, Mark Jit, Philippe Beutels, Joke Bilcke, null null
Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries. Vaccine 41 (9) (2023)
Addison E Stone, Saraswatie Rambaran, Ivy V Trinh, Marcus Estrada, Curtis W Jarand, Blake S Williams, Amelie E Murrell, Chelsea M Huerter, William Bai, Surya Palani, Yukihiro Nakanishi, Renee M Laird, Frederic M Poly, Wayne F Reed, Jessica A White, Elizabeth B Norton
Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients. Vaccine 41 (9) (2023)
Yoshifumi Uwamino, Takashi Yokoyama, Yasunori Sato, Ayako Shibata, Toshinobu Kurafuji, Akiko Tanabe, Masayo Noguchi, Tomoko Arai, Akemi Ohno, Hiromitsu Yokota, Ho Namkoong, Tomoyasu Nishimura, Kenjiro Kosaki, Naoki Hasegawa, Masatoshi Wakui, Mitsuru Murata, Hiromichi Matsushita
Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine. Vaccine 41 (9) (2023)
Abraham M Getaneh, Xiao Li, Zhuxin Mao, Caroline K Johannesen, Elisa Barbieri, Jojanneke van Summeren, Xin Wang, Sabine Tong, Eugenio Baraldi, Emily Phijffer, Caterina Rizzo, Maarten van Wijhe, Terho Heikkinen, Louis Bont, Lander Willem, Mark Jit, Philippe Beutels, Joke Bilcke, null null
Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries. Vaccine 41 (9) (2023)
Hiroshi Hamada, Masaki Futamura, Hiroto Ito, Ryoko Yamamoto, Kenji Yata, Yasumasa Iwatani, Hirotaka Inoue, Noriaki Fukatsu, Hirokazu Nagai, Yoshinori Hasegawa
Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study. Vaccine 41 (9) (2023)
Yumi Tsuchiya, Hiroshi Tamura, Koji Fujii, Hirotaka Numaguchi, Kiichiro Toyoizumi, Tina Liu, Mathieu Le Gars, Vicky Cárdenas, Takashi Eto
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan. Vaccine 41 (9) (2023)
Yanmin Zhang, Daoyuan Na, Weijian Zhang, Xuping Liu, Shiwei Miao, Wen-Song Tan, Liang Zhao
Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform. Vaccine 41 (9) (2023)
Abraham M Getaneh, Xiao Li, Zhuxin Mao, Caroline K Johannesen, Elisa Barbieri, Jojanneke van Summeren, Xin Wang, Sabine Tong, Eugenio Baraldi, Emily Phijffer, Caterina Rizzo, Maarten van Wijhe, Terho Heikkinen, Louis Bont, Lander Willem, Mark Jit, Philippe Beutels, Joke Bilcke, null null
Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries. Vaccine 41 (9) (2023)
Mathurin Seesen, Tuksin Jearanaiwitayakul, Jitra Limthongkul, Panuwat Midoeng, Panya Sunintaboon, Sukathida Ubol
A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells. Vaccine 41 (9) (2023)
A Patricia Wodi, Paige Marquez, Adamma Mba-Jonas, Faith Barash, Kosal Nguon, Pedro L Moro
Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS). Vaccine 41 (9) (2023)
A Zabalza-Baranguá, I Poveda-Urkixo, S Mena-Bueno, G A Ramírez, X De Bolle, M J Grilló
Vaccine properties of Brucella melitensis 16MΔwzm and reactivation of placental infection in pregnant sheep. Vaccine 41 (9) (2023)
Yanmin Zhang, Daoyuan Na, Weijian Zhang, Xuping Liu, Shiwei Miao, Wen-Song Tan, Liang Zhao
Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform. Vaccine 41 (9) (2023)
Addison E Stone, Saraswatie Rambaran, Ivy V Trinh, Marcus Estrada, Curtis W Jarand, Blake S Williams, Amelie E Murrell, Chelsea M Huerter, William Bai, Surya Palani, Yukihiro Nakanishi, Renee M Laird, Frederic M Poly, Wayne F Reed, Jessica A White, Elizabeth B Norton
Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients. Vaccine 41 (9) (2023)
Hiroshi Hamada, Masaki Futamura, Hiroto Ito, Ryoko Yamamoto, Kenji Yata, Yasumasa Iwatani, Hirotaka Inoue, Noriaki Fukatsu, Hirokazu Nagai, Yoshinori Hasegawa
Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study. Vaccine 41 (9) (2023)
Ariella Grossman-Giron, Dana Tzur Bitan, Sharon Shemesh, Yael Mayer, Noga Shiffman, Yuval Bloch
COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel. Vaccine 41 (9) (2023)
Mathurin Seesen, Tuksin Jearanaiwitayakul, Jitra Limthongkul, Panuwat Midoeng, Panya Sunintaboon, Sukathida Ubol
A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells. Vaccine 41 (9) (2023)
James S Ford, Sam G Rouleau, Jenny L Wagner, Christopher B Adams, Larissa S May, Aman K Parikh, James F Holmes
Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department. Vaccine 41 (9) (2023)
Simon B Gressens, Aurélie Wiedemann, Marie Déchenaud, Jehan Dupuis, Sébastien Gallien, Giovanna Melica, Corinne Haioun, François Lemonnier, Yves Levy
Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies. Vaccine 41 (9) (2023)
Yumi Tsuchiya, Hiroshi Tamura, Koji Fujii, Hirotaka Numaguchi, Kiichiro Toyoizumi, Tina Liu, Mathieu Le Gars, Vicky Cárdenas, Takashi Eto
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan. Vaccine 41 (9) (2023)
A Patricia Wodi, Paige Marquez, Adamma Mba-Jonas, Faith Barash, Kosal Nguon, Pedro L Moro
Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS). Vaccine 41 (9) (2023)
Ariella Grossman-Giron, Dana Tzur Bitan, Sharon Shemesh, Yael Mayer, Noga Shiffman, Yuval Bloch
COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel. Vaccine 41 (9) (2023)
Hiroshi Hamada, Masaki Futamura, Hiroto Ito, Ryoko Yamamoto, Kenji Yata, Yasumasa Iwatani, Hirotaka Inoue, Noriaki Fukatsu, Hirokazu Nagai, Yoshinori Hasegawa
Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study. Vaccine 41 (9) (2023)
Simon B Gressens, Aurélie Wiedemann, Marie Déchenaud, Jehan Dupuis, Sébastien Gallien, Giovanna Melica, Corinne Haioun, François Lemonnier, Yves Levy
Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies. Vaccine 41 (9) (2023)
Mathurin Seesen, Tuksin Jearanaiwitayakul, Jitra Limthongkul, Panuwat Midoeng, Panya Sunintaboon, Sukathida Ubol
A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells. Vaccine 41 (9) (2023)
Ami Harbin, Naomi Laventhal, Mark Navin
Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19. Vaccine 41 (9) (2023)
A Zabalza-Baranguá, I Poveda-Urkixo, S Mena-Bueno, G A Ramírez, X De Bolle, M J Grilló
Vaccine properties of Brucella melitensis 16MΔwzm and reactivation of placental infection in pregnant sheep. Vaccine 41 (9) (2023)
A Patricia Wodi, Paige Marquez, Adamma Mba-Jonas, Faith Barash, Kosal Nguon, Pedro L Moro
Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS). Vaccine 41 (9) (2023)
Addison E Stone, Saraswatie Rambaran, Ivy V Trinh, Marcus Estrada, Curtis W Jarand, Blake S Williams, Amelie E Murrell, Chelsea M Huerter, William Bai, Surya Palani, Yukihiro Nakanishi, Renee M Laird, Frederic M Poly, Wayne F Reed, Jessica A White, Elizabeth B Norton
Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients. Vaccine 41 (9) (2023)
Srihari Seshadri, Stacey W Martin, Susan L Hills, Limone C Collins
Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019. Vaccine 41 (9) (2023)
Srihari Seshadri, Stacey W Martin, Susan L Hills, Limone C Collins
Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019. Vaccine 41 (9) (2023)
Yumi Tsuchiya, Hiroshi Tamura, Koji Fujii, Hirotaka Numaguchi, Kiichiro Toyoizumi, Tina Liu, Mathieu Le Gars, Vicky Cárdenas, Takashi Eto
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan. Vaccine 41 (9) (2023)
María Gabriela Matta, Laura Pulido, Juan José Herrera-Paz, José M Picco, Sebastian Wolff, Gary Tse, Sebastian Garcia-Zamora
Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina. Vaccine 41 (9) (2023)
A Zabalza-Baranguá, I Poveda-Urkixo, S Mena-Bueno, G A Ramírez, X De Bolle, M J Grilló
Vaccine properties of Brucella melitensis 16MΔwzm and reactivation of placental infection in pregnant sheep. Vaccine 41 (9) (2023)